Oilon: HVAC Industry Leader Goes With Environmentally Friendly Heat Pump Technology Developed in Finland
16.12.2021 10:00:00 EET | Business Wire | Press release
Oilon, the Finnish energy and environmental technology company, has signed a collaboration agreement with Trane®, a leading global provider of indoor comfort solutions and services and a brand of Trane Technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211215005409/en/
In November 2021, Oilon opened a new plant for manufacturing industrial heat pumps in Kokkola (Finland). The capacity of the new plant is four times higher than the existing one. (Photo: Business Wire)
As part of the agreement, Trane will offer in Europe the Trane Exergy Series heat pumps designed and manufactured in collaboration with Oilon. The Exergy Series units deliver heating capacity of up to 120 degrees Celsius and can replace oil and gas boilers in industrial process, buildings and district heating applications.
– "Hardly any companies have managed to develop environmentally friendly technologies capable of such high temperatures. Cooperation with one of the world's largest players in the industry will help us to promote this sustainable technology more and more widely," says Martti Kukkola, Chief Business Officer for Oilon's Industrial Heat Pumps and Chillers.
Heat pumps are indeed regarded as one of the most significant means of producing fossil-free energy in the process industry and energy companies.
– "The agreement is a great reward for the long-term work we have done for over a decade to develop carbon-neutral energy production technologies", Kukkola adds.
In November 2021, Oilon opened a new plant for manufacturing industrial heat pumps in Kokkola (Finland). The capacity of the new plant is four times higher than the existing one.
Moreover, it will further accelerate the development of the industrial heat pump business, where Oilon has seen a notable expansion in recent years: deliveries grew significant. At present, the greatest demand comes from the European market, the needs of which are met by cooperation with Trane.
– "We have aggressive growth targets in industrial heat pumps, which are expected to become Oilon's core business in a few years' time. With such prospects, the capacity of the new plant will only be enough for a couple of years," Kukkola reckons.
Contact:
Oilon is a family-owned, global energy and environmental technology company, founded in 1961. Oilon specialises in energy and environmental technology with focus on industrial heat pumps and chillers, ground source heat pumps, and burners and combustion systems. Oilon conducts continuous product development to improve energy efficiency, reduce emissions and create solutions based on renewable energy sources.
Oilon has a of €70 million turnover and employs 380 people. The company has production facilities in Finland, the United States, China and Russia, as well as sales offices in Brazil and Germany. Furthermore, Oilon runs an international sales network of 70 dealers.
About Trane
Trane – by Trane Technologies (NYSE: TT), a global climate innovator – creates comfortable, energy efficient indoor environments for commercial and residential applications. For more information, please visit www.trane.eu or www.tranetechnologies.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211215005409/en/
Contact information
Martti Kukkola – Chief Business Officer
Industrial heat pumps and chillers
Oilon Oy
Tel. +358 3 85 761, Mob. +358 400 312 060
martti.kukkola@oilon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom